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ABSTRACT Hemagglutinin (HA) of inﬂuenza virus must be activated by proteolysis
before the virus can become infectious. Previous studies indicated that HA cleavage
is driven by membrane-bound or extracellular serine proteases in the respiratory
tract. However, there is still uncertainty as to which proteases are critical for activat-
ing HAs of seasonal inﬂuenza A viruses (IAVs) in humans. This study focuses on hu-
man KLK1 and KLK5, 2 of the 15 serine proteases known as the kallikrein-related
peptidases (KLKs). We ﬁnd that their mRNA expression in primary human bronchial
cells is stimulated by IAV infection. Both enzymes cleaved recombinant HA from sev-
eral strains of the H1 and/or H3 virus subtype in vitro, but only KLK5 promoted the
infectivity of A/Puerto Rico/8/34 (H1N1) and A/Scotland/20/74 (H3N2) virions in
MDCK cells. We assessed the ability of treated viruses to initiate inﬂuenza in mice.
The nasal instillation of only the KLK5-treated virus resulted in weight loss and lethal
outcomes. The secretion of this protease in the human lower respiratory tract is en-
hanced during inﬂuenza. Moreover, we show that pretreatment of airway secretions
with a KLK5-selective inhibitor signiﬁcantly reduced the activation of inﬂuenza
A/Scotland/20/74 virions, providing further evidence of its importance. Differently,
increased KLK1 secretion appeared to be associated with the recruitment of inﬂam-
matory cells in human airways regardless of the origin of inﬂammation. Thus, our
ﬁndings point to the involvement of KLK5 in the proteolytic activation and spread of
seasonal inﬂuenza viruses in humans.
IMPORTANCE Inﬂuenza A viruses (IAVs) cause acute infection of the respiratory tract
that affects millions of people during seasonal outbreaks every year. Cleavage of the
hemagglutinin precursor by host proteases is a critical step in the life cycle of these
viruses. Consequently, host proteases that activate HA can be considered promising
targets for the development of new antivirals. However, the speciﬁc proteases that
activate seasonal inﬂuenza viruses, especially H3N2 viruses, in the human respiratory
tract have remain undeﬁned despite many years of work. Here we demonstrate that
the secreted, extracellular protease KLK5 (kallikrein-related peptidase 5) is efﬁcient in
promoting the infectivity of H3N2 IAV in vitro and in vivo. Furthermore, we found
that its secretion was selectively enhanced in the human lower respiratory tract dur-
ing a seasonal outbreak dominated by an H3N2 virus. Collectively, our data support
the clinical relevance of this protease in human inﬂuenza pathogenesis.
KEYWORDS inﬂuenza virus, proteases
Human inﬂuenza A and B viruses cause inﬂuenza, a highly contagious respiratoryillness that affects millions of people worldwide during seasonal epidemics. The
subtype of an inﬂuenza A virus (IAV) depends on the antigenic properties of its
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hemagglutinin (HA) and neuraminidase (NA) glycoproteins. There are currently 18 HA
subtypes (H1 to H18) and 11 NA subtypes (N1 to N11) known in birds and mammals.
Seasonal infections in humans are caused mostly by strains of two virus subtypes, H1N1
and H3N2.
Inﬂuenza A virus infection is initiated by the binding of virus HA to sialic acid
receptors on the surface of host cells; the human-adapted subtypes bind preferably to
2,6-linked sialic acid. The bound virus enters the host cell by endocytosis and then
moves through the endosomal network. The acidic environment in the endosome
triggers conformational changes in HA that expose the fusion peptide, which leads to
virus-endosome fusion. The fusion of the virus and endosomal membranes results in
the release of the virus genome and associated proteins into the cytosol. From there,
they are trafﬁcked to the nucleus, where they replicate (reviewed in reference 1). HA is
initially synthesized as a precursor, HA0, that is subsequently cleaved by host proteases
to give the mature HA1/HA2 form, a complex of two disulﬁde-linked subunits. This
proteolytic activation of HA is essential for the fusion of the virus envelope with
endosomal membranes and, hence, for the production of infective virus. The HAs of all
human seasonal inﬂuenza virus strains have a single arginine at their cleavage sites, and
several trypsin-like serine proteases from human bronchial/tracheal epithelial cells can
activate monobasic HA in vitro. These serine proteases include several members of the
type II transmembrane serine protease (TTSP) family (2), TMPRSS2, TMPRSS2 isoform 1,
TMPRSS4, matriptase, DESC1, MSPL, and HAT (human airway trypsin-like protease)
(3–5), and two secreted kallikrein-related proteases (KLKs), namely, KLK5 and KLK12 (6).
The blood proteases plasmin, urokinase, plasma kallikrein, and thrombin also cleave
and activate HA in vitro (7), but there is still some uncertainty as to which proteases
support the multicycle replication of seasonal IAVs in the human respiratory system.
Although TMPRSS2 is a marker of susceptibility to severe A (H1N1)pdm09 inﬂuenza
virus (8), there is no clinical data indicating the involvement of a speciﬁc protease in the
activation of seasonal IAV. However, in mice, TMPRSS2 has been identiﬁed as being
essential for the spread of H1N1 IAV (9–11) and of H3N2 IAV in association with
TMPRSS4 (12).
The kallikrein-related peptidase family comprises 15 secreted serine proteases (KLK1
to KLK15). Most KLKs are produced by the epithelia of the upper and lower respiratory
tracts (nose, paranasal sinuses, larynx, trachea, and bronchial tree) and by the submu-
cosal glands of the main airways (13, 14). However, little is known of their expression
or function under pathophysiological conditions. We have examined the expressions of
9 KLK genes in human airway epithelia reconstituted in vitro and infected with IAV. As
the amounts of the mRNAs encoding KLK1 and KLK5 were selectively increased
following IAV infection, we explored the contribution of these proteases to seasonal ﬂu.
They usually cleave their substrates after a basic residue, with a preference for Arg. We
therefore investigated their ability to cleave and activate HAs from several strains of
H1N1 and H3N2 viruses in vitro and in vivo. Finally, we analyzed samples of human
tracheal aspirates (TAs) to determine whether the secretion of KLK1 and KLK5 in the
lower respiratory tract was dysregulated during seasonal inﬂuenza.
RESULTS
Selective induction of KLK1 and KLK5 mRNAs in human bronchial epithelial
cells during inﬂuenza virus infection. Airway epithelial cells are both the target of
inﬂuenza virus and where KLKs are synthesized. We checked to see whether viral
infection modulated the expressions of certain KLK-encoding genes. As a preliminary
study showed that KLK2, KLK3, KLK4, KLK6, KLK12, and KLK15 are poorly expressed in
normal lung tissue, we focused on the genes encoding the other 9 KLK genes. We
infected human bronchial epithelia reconstituted in vitro with inﬂuenza A/Scotland/
20/74 (H3N2) virus, and the mRNA expression levels of KLK1, -5, -7, -8, -9, -10, -11, -13,
and -14 were analyzed by reverse transcription-quantitative PCR (RT-qPCR) (Fig. 1). IAV
infection signiﬁcantly increased the amounts of mRNAs encoding KLK1 and KLK5 and
decreased the amounts of KLK13 and KLK14 mRNAs. The level of KLK9 also tended to
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decrease (P  0.082). These data indicate that IAV infection differentially regulates the
gene expression of members of the KLK family in the epithelium of the lower respira-
tory tract. Because the expression levels of KLK1 and KLK5 were increased by IAV, we
looked at the possibility that these serine proteases could be beneﬁcial for the virus.
Cleavage of seasonal inﬂuenza virus HA by KLK1 and KLK5. HA is initially
synthesized as a precursor, HA0, that is subsequently cleaved by host enzymes to give
its functional forms, HA1 and HA2. Therefore, we compared the abilities of KLK1 and
KLK5 to cleave recombinant HA precursors from ﬁve strains of subtype H1 inﬂuenza
virus (Fig. 2A) and four strains of the H3 subtype (Fig. 2B). Trypsin was used as a control
(not shown) because this enzyme cleaves most HAs to generate two fragments with
apparent molecular masses of 55 kDa (HA1) and 25 kDa (HA2).
Of the 9 HA precursors, only 4 (A/Brisbane/59/07, A/California/07/09, A/Puerto
Rico/8/34 [A/PR/8/34], and A/Solomon Island/3/06) were signiﬁcantly digested by KLK1.
However, the fragmentation patterns of several precursors contained bands in addition
to those of the HA1 and HA2 fragments. Thus, KLK1 can cleave these HAs at other sites.
Conversely, KLK5 speciﬁcally generated HA1 and HA2 fragments from all HAs, although
their production rates varied. We ﬁnd that KLK5 most actively cleaved HAs from H1
subtype strains A/Brisbane/59/07, A/California/07/09, A/Puerto Rico/8/34, and A/Solo-
mon Island/3/06 and from H3 subtype strain A/Wisconsin/67/05. Despite their prefer-
ence for cleavage after an arginine residue, the spectra of HA cleavage by KLK1 and
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FIG 1 Inﬂuence of IAV infection on KLK gene expression in reconstituted human bronchial epithelium.
mRNAs encoding KLKs in differentiated bronchial cells cultured at the air-liquid interface that were
infected with inﬂuenza A/Scotland/20/74 virus (MOI 1) (IAV) or not (mock) were assayed by RT-qPCR.
The data represent the means  standard errors of the means (n  8). Statistical conﬁdence was
measured by using a Mann-Whitney U test. *, P  0.05; **, P  0.01; ns, nonsigniﬁcant.
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KLK5 in vitro appeared to differ. KLK1 seemed to prefer the H1 subtype, while KLK5
efﬁciently cleaved both the H1 and H3 subtypes (Fig. 2C). This is consistent with
previously reported observations that all KLKs have unique speciﬁcity proﬁles due to
subtle differences in their active sites (15). Each peptidase also seemed to prefer
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FIG 2 Cleavage of HA subtypes. (A and B) SDS-PAGE and silver staining analyses of intact HA and HA cleaved by human
recombinant KLK1 or KLK5. Lanes from the gel images were cut and spliced together with Adobe Photoshop CS 5.1 to aid
in band comparison. The recombinant HAs were from H1 subtype strains A/Brisbane/59/07 (Br/59/07), A/California/07/09
(Ca/07/09), A/New Caledonia/20/99 (NC/20/99), A/Puerto Rico/8/34 (PR/8/34), and A/Solomon Island/03/06 (SI/03/06) (A)
and from H3 subtype strains A/Aichi/2/68 (Ai/2/68), A/Brisbane/10/07 (Br/10/07), A/Wisconsin/67/05 (Wi/67/05), and
A/Wyoming/3/03 (A/Wy/3/03) (B). (C) Efﬁciency of HA cleavage by KLKs. The bar graph depicts the amount of the HA1
fragment generated by KLK cleavage of all the HAs examined. The values were determined by densitometry analysis in 3
distinct silver staining experiments (means standard errors of the means). (D) Alignment of the sequences in the vicinity
of the proteolytic cleavage site of HAs.
Magnen et al. Journal of Virology
August 2017 Volume 91 Issue 16 e00421-17 jvi.asm.org 4
 o
n
 August 1, 2018 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
particular strains within the H1 and/or H3 subtype. The amino acid sequences close to
the cleavage site (Fig. 2D) do not seem to be responsible for these preferences because
some HAs that had the same sequences were cleaved very differently. This is clearly
illustrated by the A/New Caledonia/20/99 and A/Solomon Islands/03/06 HAs; they were
not cleaved at the same rate by KLK1, although the amino acid sequences around their
cleavage sites are identical. Other factors, such as the three-dimensional (3D) structure
of each HA, must inﬂuence cleavage preference.
KLK5 promotes the infectivity of seasonal inﬂuenza A viruses. We checked the
abilities of KLK1 and KLK5 to make noninfectious inﬂuenza A virions infective in order
to examine the functional consequences of HA cleavage. The virions were ﬁrst incu-
bated with trypsin, KLK1, or KLK5. The treated virions were then incubated with
mammalian cells, and the amounts of inﬂuenza virus nucleoprotein in the cells were
detected by ﬂow cytometry (Fig. 3A and B). Both trypsin and KLK5 activated the
A/Scotland/20/74 (H3N2) virus, resulting in infected cells. Pretreatment of the virions
with KLK1 did not increase cell infection; infection was the same as that produced by
untreated viruses. These observations were conﬁrmed by immunocytochemistry (Fig.
3C) and RT-qPCR (Fig. 3D).
Uncleaved inﬂuenza A/PR/8/34 (H1N1) HA virions were also treated with the pro-
teases, and the nucleoprotein (NP) mRNA that accumulated in infected Madin-Darby
canine kidney (MDCK) cells was quantiﬁed by RT-qPCR. Treatment of A/PR/8/34 virions
with KLK5 slightly stimulated NP mRNA production, but incubation with KLK1 had no
effect (Fig. 3E). Thus, KLK5 can activate H1 and H3 subtype IAVs, increasing their in
cellulo infectivity. This protease activates H3 subtypes preferentially. In contrast, KLK1
did not promote the multicycle replication of inﬂuenza viruses used in this study.
To determine whether KLK5 naturally secreted by bronchial cells may activate
inﬂuenza virus, we incubated inﬂuenza A/Scotland/20/74 virions with supernatants of
unchallenged 16HBE14o cells containing around 60 ng/ml of KLK5. MDCK cells were
then infected with the treated virions. As shown in Fig. 3F, treatment of the virions with
the 16HBE14o supernatant increased cell infection; this effect was signiﬁcantly re-
duced when the virions were incubated with the supernatant pretreated with SFTI-
FCHR, a synthetic inhibitor of KLK5. This molecule does not inhibit previously identiﬁed
HA-activating soluble proteases such as plasma kallikrein, plasmin, thrombin, and
matriptase and denotes a greater preference for KLK5 than for trypsin (Ki  6.2  0.2
versus 31.5  1.4).
KLK5-treated H3N2 virus initiates viral infection in mice. Although MDCK cells
are commonly used to characterize the infectivity of inﬂuenza viruses, they are not the
natural host cells of these viruses. We therefore examined the abilities of viruses treated
with KLK1 or KLK5 to trigger acute pneumonia in mouse models. C57BL/6 mice were
inoculated intranasally with inﬂuenza A/PR/8/34 (H1N1) or inﬂuenza A/Scotland/20/74
(H3N2) viruses that had been incubated with trypsin, human KLK1, or human KLK5 or
left untreated (controls), and their weights and survival rates were monitored (Fig. 4).
Neither unactivated H1N1 virus nor KLK-treated H1N1 virus caused any signiﬁcant
weight loss or death, but trypsin-treated virus triggered acute pneumonia, with a death
rate of 50% (Fig. 4A). H3N2 virus pretreated with human KLK1 did not modify the
weight loss or survival of mice; its effect was the same as that of the unactivated H3N2
virus (Fig. 4B). Conversely, mice infected with KLK5-treated H3N2 viruses lost weight
from the third day postinfection, in parallel with the weight loss caused by trypsin-
treated viruses. Signiﬁcantly more mice inoculated with trypsin-treated or KLK5-treated
H3N2 viruses died than did mice infected with the unactivated virus.
Inﬂuenza and secretion of KLK1 and KLK5 in the human lower respiratory tract.
We measured the amounts of KLK1 and KLK5 in the secretions of the lower respiratory
tract of inﬂuenza virus-infected humans in order to assess the impact of infection on
the secretion of these proteases. We analyzed tracheal aspirate samples from 17
patients in an intensive care unit as a result of 2014-2015 seasonal inﬂuenza and
aspirate samples from 18 patients hospitalized in the intensive care unit for noninfec-
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tious reasons. The intensities of inﬂammation, as assessed by the number of total cells
and myeloperoxidase (MPO), interleukin-6 (IL-6), and IL-8 concentrations, were similar
in the two groups. All the samples contained signiﬁcant amounts of KLK1 and KLK5, but
the KLK5 concentration in the tracheal aspirate samples from ﬂu patients was signiﬁ-
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FIG 3 Activation of H1N1 and H3N2 inﬂuenza viruses by KLKs. (A to C) MDCK cells were infected with A/Scotland/20/74 (H3N2)
particles that had been treated by incubation with either trypsin or speciﬁc KLKs for 1 h at 37°C. The resulting MDCK cells were
collected and stained for inﬂuenza virus nucleoprotein with anti-nucleoprotein-FITC (NP-FITC) mouse IgG1. FSC-A, forward
scatter area. (A and B) Representative proﬁles of inﬂuenza virus nucleoprotein expression (A) and ﬂuorescence data (B) were
acquired by using a MACS Quant ﬂow cytometer. (C) Immunoﬂuorescence staining results. The inﬂuenza virus nucleoprotein
was detected with anti-nucleoprotein-FITC antibody (green), and nuclei were stained with Hoechst 33258 (blue). (D and E)
MDCK cells were infected with inﬂuenza A/Scotland/20/74 (H3N2) (D) or inﬂuenza A/Puerto Rico/8/34 (H1N1) (E) virus particles
that had been incubated with TPCK-treated trypsin or a KLK for 2 h at 37°C. The resulting MDCK cells were collected, and the
mRNA encoding the inﬂuenza virus nucleoprotein was assayed by RT-qPCR. Results were expressed as percentages of values
obtained with trypsin-treated virus. Means  standard errors of the means are shown (n  12). (F) MDCK cells were infected
with inﬂuenza A/Scotland/20/74 virus particles that had been pretreated with supernatants (n  8) of human bronchial
epithelial cells (16HBE14o) in the absence ( supernatant) or in the presence ( supernatant  Inh) of a selective KLK5
inhibitor for 16 h at 37°C. Proportions of infected MDCK cells were determined by ﬂow cytometry using an anti-NP-FITC
antibody. Results are expressed as fold changes of values obtained with the untreated virus (control [Ctrl]). Data were analyzed
by one-way ANOVA followed by Tukey’s multiple-comparison test (*, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001).
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cantly elevated (Fig. 5A). The molecular pattern of KLK5 in aspirate samples was then
analyzed by Western immunoblotting. We found two main immunoreactive bands, one
at about 55,000 Da and the other at 35,000 Da. The upper band is consistent with a
form of KLK5 covalently complexed with a protease inhibitor, while the lower band
corresponds to free, possibly active, KLK5. By normalizing the values to the total protein
concentration present in each lane, immunoblotting revealed that the concentration of
free KLK5 was selectively increased in ﬂu patients (Fig. 5C), modifying the ratio of free
to complexed KLK5 (Fig. 5D). Finally, tracheal aspirate samples from noninfected
patients were pretreated with the vehicle or with a KLK5-selective inhibitor and then
incubated with inﬂuenza A/Scotland/20/74 virions. Figure 5E shows that pretreatment
of aspirates with SFTI-FCHR signiﬁcantly reduced infection of MDCK cells. Collectively,
these observations suggest that IAV infection likely disrupts the balance between KLK5
and its inhibitor(s) in the lower respiratory tract and that the residual activity of KLK5
can cause the proteolytic activation of inﬂuenza virus.
KLK1 and KLK5 are secreted by two distinct cell compartments. The cells
responsible for the KLKs in inﬂamed lungs have yet to be clearly identiﬁed. KLKs seem
to be produced by the surface epithelium and the submucosal glands of airways (14),
but KLKs have also been detected in circulating neutrophils (16). We ﬁrst examined the
distribution of KLK1 and KLK5 in immune cells in tracheal aspirates by ﬂow cytometry.
Neutrophils and T and B lymphocytes all contained substantial amounts of KLK1, but it
was less abundant in macrophages and NK cells (Fig. 6A). Because neutrophils are the
major immune cells in inﬂamed airways, we then looked for a correlation between the
concentrations of KLK1 in the aspirates and the neutrophil abundance estimated by
measuring the MPO concentration. We found a signiﬁcant positive correlation for KLK1
(Fig. 6A), indicating that neutrophils are the main source of KLK1 in inﬂamed airways.
In contrast, there was little KLK5 in immune cells, and there was no correlation between
the amounts of KLK5 and MPO in the tracheal aspirates (Fig. 6B). Thus, immune cells
contribute little to the KLK5 secreted into inﬂamed airways, and the main source of KLK5
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FIG 4 Effect of KLK-activated viruses in mice. Shown are body weight kinetics and survival of mice
infected with viruses that had been treated with TPCK-treated trypsin, human KLK1, or human KLK5. Male
C57BL/6 mice (n  6 per group) were inoculated intranasally with inﬂuenza A/Puerto Rico/8/34 (H1N1)
(A) or inﬂuenza A/Scotland/20/74 (H3N2) (B) virus. *, P  0.05; **, P  0.01 (for treated versus untreated
mice, as determined by Kaplan-Meier and log rank [Mantel-Cox] tests).
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FIG 5 KLKs in lower respiratory tract secretions. (A) Total cell numbers and concentrations of
myeloperoxidase, inﬂammatory mediators (IL-6 and IL-8), and KLKs were measured in tracheal
aspirate samples from control patients (No Flu) (n  18) and inﬂuenza patients (Flu) (n  17) in an
intensive care unit. Means  standard errors of the means are shown. **, P  0.01, as determined
by a Mann-Whitney U test. (B) Western blot analysis of KLK5 in tracheal aspirates from patients in an
intensive care unit. Lanes from the gel images were cut and spliced together with Adobe Photoshop
CS 5.1 to aid in band comparison. Numbers at the left refer to molecular masses, in kilodaltons. (C)
Densitometric analysis of the Western blot data shown in panel B. The values (AU, arbitrary units)
represent the signal intensity normalized against the total protein amount in each lane assessed by
Ponceau S staining after membrane transfer. (D) Ratio of free to bound KLK5. (E) MDCK cells were
infected with inﬂuenza A/Scotland/20/74 virus particles that had been pretreated with supernatants
(n  9) of human tracheal aspirates (TA) in the absence or in the presence of a selective KLK5
inhibitor (TA  Inh) for 16 h at 37°C. Proportions of infected MDCK cells were determined by ﬂow
cytometry using an anti-NP-FITC antibody. Results are expressed as fold changes of values obtained
without an inhibitor. Data were analyzed by a Mann-Whitney U test (**, P  0.01).
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during IAV infection is probably the airway mucosa. This assumption is supported by the
induction of KLK5 in human bronchial epithelial cells (hBECs) infected with IAV (Fig. 6C). Our
data indicate that infection of the human lower respiratory tract by IAV stimulates the
synthesis and secretion of the IAV-activating protease KLK5 by the airway epithelium.
DISCUSSION
Numerous groups have reported that various members of the TTSPs are respon-
sible for activating several seasonal inﬂuenza viruses (3, 4, 10, 17, 18). Bottcher-
Friebertshauser et al. used MDCK cells to show that TMPRSS2 cleaves HA within
cells, while HAT cleaves HA at the cell surface (19). All these ﬁnding suggest that HA
cleavage is cell associated, but there is still no direct clinical evidence for the cell-
associated activation of seasonal inﬂuenza virions in the human respiratory system. A
recent report showing that the TMPRSS2 gene is a marker of susceptibility to severe
2009 pandemic A(H1N1) inﬂuenza virus indicates that TMPRSS2 contributes to inﬂu-
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FIG 6 Sources of the KLKs secreted into inﬂamed lower respiratory tracts. (A and B, left) Flow cytometric
analysis of KLK1 and KLK5 expression in immune cells in tracheal aspirates (Ctrl, negative-control cells;
PNN, polynuclear neutrophils; Macro, macrophages; NK, NK cells; LT, T lymphocytes; LB, B lymphocytes;
MFI, mean ﬂuorescence intensity). All values are means  standard errors of the means from 3
independent experiments. (Right) Correlation between KLK and MPO concentrations in tracheal aspirate
samples. Correlation was tested by a Spearman rank test. (C) Flow cytometric analysis of KLK5 expression
in differentiated bronchial cells cultured at the air-liquid interface and infected with inﬂuenza A/Scot-
land/20/74 virus at different MOIs. Fluorescence data were acquired by using a MACS Quant ﬂow
cytometer; means  standard errors of the means are shown (n  4). Data were analyzed by one-way
ANOVA followed by Tukey’s multiple-comparison test (**, P  0.01).
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enza virus pathogenesis in humans (8). In contrast, soluble activating proteases have
been found in the secretions of the upper respiratory tract (20, 21), and several groups
have attempted to identify them. Secreted forms of TMPRSS2 and HAT have been
observed, but their catalytic activities are uncertain (19, 20, 22). Conversely, Hamilton et
al. showed that the secreted catalytic domain of matriptase cleaved and activated HA
from H1 subtype inﬂuenza virus in vitro (23). Hamilton and Whittaker also identiﬁed
human KLK5 and human KLK12 as possible activators of seasonal inﬂuenza viruses (6).
At present, 3 human KLKs (KLK1, KLK5, and KLK12) have been examined for their ability to
cleave HA and activate inﬂuenza A viruses. Collectively, data from previous studies and our
present ﬁndings clearly demonstrate that these KLKs are highly selective and do not cleave
HA from the H1 and H3 inﬂuenza A virus subtypes with the same efﬁciency. Human KLK1
cleaves H1 subtype HAs best, and KLK5 cleaves a wide range of both H1 and H3 subtype
HAs, while KLK12 cleaves H1 and H2 subtype HAs most efﬁciently. This may reﬂect, at least
in part, the distinct speciﬁcity of each KLK for substrate recognition motifs. However, the
amino acid sequence ﬂanking the cleavage site does not appear to be the sole determinant
of HA cleavage preference. Indeed, the efﬁciency with which HAs that have the same amino
acid residues in the vicinity of the cleavage site were hydrolyzed varied. The crystal
structures of HA0s from different HA subtypes indicate that the cleavage site forms a loop
more or less exposed to the environment. The ﬂexibility and accessibility of this loop are
believed to contribute to the differences in the susceptibilities of subtypes to proteases (24).
As IAVs vary enormously, there may be subtle differences in the loop conformations of HAs
of the same subtype, and this could result in interstrain variations in the cleavage efﬁciency.
Clearly, more work is needed to determine the factors that govern the susceptibilities of
closely related HAs to a given protease.
We examined viral infectivity in cellulo using MDCK cells to establish whether the
cleavage of virus HA by KLK1 and KLK5 was correlated with this infectivity. Human KLK1
did not activate uninfectious H1N1 A/Puerto Rico/8/34 or H3N2 A/Scotland/20/74
virions. This contrasts with a previous report that rat Klk1 enhances virus production in
MDCK cells infected with inﬂuenza A/WSN/33 (H1N1) virus particles (25). This may be
because of differences in the substrate speciﬁcities of rat Klk1 and human KLK1 (26).
Alternatively, the divergent results may illustrate differences in the cleavage suscepti-
bilities of A/Puerto Rico/8/34 HA and A/WSN/33 HA. Compared to other H1N1 strains,
A/WSN/33 HA does not have the typical cleavage motif but possesses a tyrosine at the
P2 position (Fig. 3D). Such a Ser-Tyr mutation enhances plasmin-mediated cleavage and
virus activation of naturally occurring H1N1 inﬂuenza viruses (27). It is possible that this
mutation has similar consequences for KLK1-mediated viral activation. Our results also
indicate that KLK5 activates HAs of both the H1 and H3 subtypes so that KLK5-treated
viruses can infect MDCK cells. However, KLK5 activates H3N2 inﬂuenza A/Scotland/
20/74 virus more efﬁciently than it activates H1N1 inﬂuenza A/Puerto Rico/8/34 virus.
This preference for the H3 subtype is consistent with a previous report showing that
KLK5 produced greater fusogenic activity with H3 subtype HAs than with HAs of the H1
and H2 subtypes (6). In contrast, KLK12 cleaves H1 and H2 subtype HAs most efﬁciently.
It does not promote the infectivity of A/Scotland/20/74 (H3N2) virions (data not shown),
conﬁrming the report by Hamilton et al. that it does not activate HAs of the H3 subtype.
Our next step was to examine the ability of treated viruses to promote inﬂuenza
virus infection in vivo in mice. We conﬁrmed that KLK1 did not functionally activate
A/Puerto Rico/8/34 and A/Scotland/20/74 viruses belonging to the H1 and H3 subtypes.
Acute pneumonia was observed in mice instilled with inﬂuenza A/Scotland/20/74
viruses that had been activated by KLK5. Weight loss and mortality were then identical
to those obtained with trypsin-activated viruses. Thus, human KLK5 causes H3 subtype
viruses to become very infective in the respiratory tract. Because KLK5 treatment of
virions impacted only the ﬁrst round of infection, endogenous proteases were therefore
involved in subsequent viral spread and pathogenesis. TMPRSS2 appears to be essential
for inﬂuenza H1N1 virus to be pathogenic in mice but not for H3N2 virus pathogenicity
(9). H1N1 virus replication was suppressed in the respiratory tract of TMPRSS2/mice,
while H3N2 virus replication was only marginally affected (11). It was recently proposed
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that TMPRSS4 plus TMPRSS2 activate H3N2 viruses in mice (12). We now need to know
whether some endogenous kallikreins are involved in the replication and pathogenesis
of H3 subtype inﬂuenza viruses in mice.
Inﬂuenza pneumonia resulted in the hospitalization of a signiﬁcant number of
patients in intensive care units in Europe during the 2014-2015 winter dominated by a
human inﬂuenza A (H3N2) virus (28). Seventeen intubated patients suffering from acute
inﬂuenza and 18 patients hospitalized in the intensive care unit for other reasons
(controls) were enrolled in this study. We quantiﬁed the KLK1 and KLK5 concentrations
in tracheal aspirate samples collected from these patients. Both KLKs were present in
secretions, but the concentration of only KLK5 was signiﬁcantly increased in inﬂuenza
patients. This was not due to differences in the intensity of inﬂammation because we
measured similar amounts of total cells, MPO, IL-6, and IL-8 in both groups. The
augmented amount of luminal KLK5 is probably due to increased KLK5 production and
secretion by airway epithelial cells in response to viral infection, as indicated by our
experiments using primary cultures of bronchial cells. This mechanism might amplify
both virus activation and subsequent spread, since we have shown that KLK5 that is
naturally secreted can functionally activate noninfectious viral particles. However,
pretreatment of respiratory tract secretions with a KLK5-selective inhibitor did not
completely abolish the activation of inﬂuenza A/Scotland/20/74 virions, suggesting that
other secreted proteases might contribute to IAV activation in the lower respiratory
tract. Their identity, however, remains to be determined.
Human KLK1 seems limited in activating seasonal viruses, unlike KLK5, and inﬂuenza
virus infection does not appear to speciﬁcally increase its secretion in human airways.
KLK1 secreted into inﬂamed airways is derived mainly from luminal neutrophils. Thus,
all proinﬂammatory factors (and not only IAV) promoting the recruitment of neutrophils
may cause the KLK1 concentration to increase. This is consistent with our observation
that all the patients, both controls and inﬂuenza sufferers, with similar degrees of lung
inﬂammation had similar KLK1 concentrations. Some reports associated KLK1 with lung
dysfunctions in inﬂammatory diseases such as asthma (29) and chronic bronchitis (30).
We now need to determine whether KLK1 plays a role in acute pneumonia, whether or
not pneumonia is induced by inﬂuenza virus.
In conclusion, we ﬁnd that the secreted, extracellular protease KLK5 is very efﬁcient
in promoting the infectivity of H3N2 seasonal inﬂuenza virus. The selective ampliﬁca-
tion of KLK5 secretion during infection further supports the clinical relevance of this
protease in human inﬂuenza pathogenesis.
MATERIALS AND METHODS
Animals, cells, viruses, and reagents. Male C57BL/6 mice were purchased from Janvier Labs (Le
Genest-Saint-Isle, France). Mice were housed under pathogen-free conditions at the animal facility of F.
Rabelais University and handled according to guidelines of the European Animal Care and Use Com-
mittee (Ethical Comity agreement CEEA VdL 2012-12-6). Animals were kept in a 12-h-light–12-h-dark
cycle with food and water ad libitum.
Normal primary human bronchial epithelial cells (hBECs) and media were purchased from Lonza
(Basel, Switzerland). The cells were propagated in bronchial epithelial cell growth medium (BEGM) basal
medium and differentiated by culture at the air-liquid interface (ALI) in bronchial ALI (B-ALI) differenti-
ation basal medium. The human bronchial cell line (16HBE14o) was a generous gift from D. Gruenert
(University of California, San Francisco, CA, USA). NCI-H292 cells (ATCC/LGC Standards, Teddington, UK)
and 16HBE14o cells were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS) and 50 U/ml penicillin-streptomycin. MDCK cells (ATCC/LGC Standards) were
maintained in minimal essential medium (MEM) supplemented with 10% FBS.
Mouse-adapted inﬂuenza A/Puerto Rico/8/34 (H1N1) and inﬂuenza A/Scotland/20/74 (H3N2) viruses
were gifts from the Pasteur Institute (Paris, France). TPCK (tosyl phenylalanyl chloromethyl ketone)-
treated trypsin was obtained from Worthington (Lakewood, NJ, USA). Human kallikrein 1 was obtained
from Novoprotein, and human kallikrein 5 was obtained from R&D Systems (Minneapolis, MN, USA). All
inﬂuenza A virus HAs used in this study were obtained from Sino Biological Inc. (Beijing, China). The
enzyme-linked immunosorbent assay (ELISA) kits usedwere a human KLK1 (hKLK1) kit from Cloud-Clone Corp.
(Houston, TX, USA) and hKLK5, hMPO, hIL-6, and hIL-8 kits from R&D Systems (Minneapolis, MN, USA). The
KLK5 inhibitor SFTI-FCHR was provided by Jonathan Harris (Queensland University of Technology [QUT],
Brisbane, Australia).The inhibition assays were performed as previously described (31).
Tracheal aspirate collection. Aspirates were collected during routine tracheal suctioning of me-
chanically ventilated patients. Tracheal aspirate samples were collected from a total of 17 ﬂu patients
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hospitalized during the 2014-2015 inﬂuenza season in the CHRU Hospital of Tours and from 18
individuals not infected with inﬂuenza virus. This study was approved by French national bioethics
authorities (CPP-37 2012-R21). Informed written consent was obtained from each participant. Samples
were dissociated in 3 volumes of phosphate-buffered saline (PBS) and 1 mM dithiothreitol (Sigma-
Aldrich, St. Louis, MO, USA) with stirring during 1 h. After centrifugation at 790  g during 10 min, the
supernatant was picked up and stored at80°C until use. Total cells were counted on a Malassez cell and
analyzed by ﬂow cytometry. Soluble proteins from TA samples were electrophoresed on NuPAGE Novex
4 to 12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA). KLK5 was analyzed by Western blotting using an
anti-KLK5 rabbit antibody (catalog number 168340; Abcam, Cambridge, UK) and a goat anti-rabbit IgG
secondary antibody (Jackson ImmunoResearch, Suffolk, UK).
Infection of hBECs. The apical cell surface of an hBEC-ALI culture was washed twice with PBS. The
inﬂuenza virus (A/Scotland/20/74) inoculumwas added to the apical surface of hBECs at differentmultiplicities
of infection (MOIs) (MOIs of 0, 1, and 5), and the cells were incubated for 24 h at 37°C. The mRNA expression
of KLKs was analyzed by RT-qPCR, and the intracellular KLK5 content was assessed by ﬂow cytometry.
Hemagglutinin cleavage assay. To determine whether KLKs are able to cleave HA, inﬂuenza A virus
HAs were incubated with KLKs or with TPCK-treated trypsin in 100 mM Tris (pH 8) at 37°C for 4 h. The
HA/protease ratio was 10:1. Samples were subsequently analyzed by electrophoresis on 4 to 12% Bis-Tris
protein gels and silver staining (Invitrogen, Carlsbad, CA, USA). Densitometry analysis was performed by
using Multi Gauge V3.0 (Fujiﬁlm, Bois d’Arcy, France).
Virus infection assay. Noninfectious virions were obtained from a single round of replication in
HEK-293T cells, which lack proteases that are able to cleave HA and activate inﬂuenza virions (6).
HEK-293T cells were incubated with 1 ml of active viruses (MOI  1) for 1 h at 37°C. The culture medium
was removed, and cells were washed twice with PBS and incubated for 24 h in 9 ml of DMEM
supplemented 50 U/ml penicillin-streptomycin. The viral suspension was centrifuged for the withdrawal
of detached cells and stored at80°C until use. Virus titers were determined by using a modiﬁed plaque
assay method, as previously described (32). Inﬂuenza A virions with uncleaved HA were incubated with
200 nM KLK1 or KLK5 or with 40 nM trypsin for 2 h at 37°C. MDCK cells were infected with 200 l of the
protease-activated virus inoculum for 1 h at 37°C. At 7 h postinfection (p.i.), cells were lysed for RNA
preparation and viral nucleoprotein qPCR.
16HBE14o cell medium (without FBS) or bronchial aspirate samples were pretreated with the
vehicle or with SFTI-FCHR (10 M) for 1 h at 37°C and then incubated with uninfectious inﬂuenza
A/Scotland/20/74 virions for 16 h at 37°C. MDCK cells were infected with 200 l of the virus inoculum for
1 h at 37°C. At 16 h postinfection, cells were stained with a ﬂuorescein isothiocyanate (FITC)-conjugated
anti-inﬂuenza A virus NP antibody (Abcam, Cambridge, UK) for ﬂow cytometry analysis.
Viral nucleoprotein immunoﬂuorescence staining. MDCK cells were grown in chamber slides
(Labtex, Huddersﬁeld, UK) before infection and washed twice with PBS. The virus inoculum was then
incubated with the cells for 4 h. MDCK cells were ﬁxed by using 4% paraformaldehyde for 15 min at room
temperature (RT) and then permeabilized in PBS–0.1% Triton X-100 for 10 min at RT. Following a 1-h
saturation step with PBS–1% bovine serum albumin (BSA)–0.1% Tween 20, cells were stained with the
FITC-conjugated anti-NP antibody. The nuclei were stained with Hoechst 33258 (Invitrogen).
Mouse inﬂuenza A virus infection. Inﬂuenza A/Puerto Rico/8/34 and A/Scotland/20/74 mouse-
adapted virions were activated by treatment with either KLKs or trypsin as described above. Before
infection, 9- to 11-week-old mice were anesthetized by intraperitoneal injection of ketamine-xylazine (50
mg/kg of body weight and 10 mg/kg, respectively). Infection was performed by the intranasal application
of 40 l of the virus suspension in PBS (600 PFU/mice). Subsequently, survival and body weight loss were
monitored until day 13 p.i. In addition to mice that were found dead, mice with weight loss of more than
30% were euthanized and recorded as dead.
RNA preparation and real-time PCR ampliﬁcation. Total RNAs from MDCK cells, hBEC-ALI cultures,
or mouse lung tissues were extracted by using the NucleoSpin RNA kit (Macherey-Nagel, Düren, Germany),
including a step of genomic DNA digestion with DNase. Single-strand cDNA was synthesized from 1 g total
RNA from each sample with the High Capacity cDNA reverse transcription kit (Life Technologies SAS, Saint
Aubin, France). For analysis of the viral nucleoprotein mRNA, the reverse transcription step was performed
with an oligo(dT)12–18 primer (Invitrogen). mRNA levels were determined by quantitative real-time PCR with
a LightCycler 480 instrument (Roche Diagnostics, Meylan, France). The mRNA concentration was normalized
to the level of acidic ribosomal phosphoprotein mRNA (Rplp0). The primer pairs used are described in Table
1 and were obtained from Euroﬁns Genomics (Ebersberg, Germany). PCR was carried out by using 20 ng of
reverse-transcribed total RNA as the template, 0.2 M (each) forward and reverse primers, and 5 l SYBR
Premix Ex Taq (2) (TaKaRa Bio Europe, Saint-Germain-en-Laye, France) in a ﬁnal volume of 10 l. Each
reaction was performed in triplicate in white 384-well plates. The thermal protocol consisted of an initial
denaturation step at 95°C for 30 s followed by 40 cycles of denaturation at 95°C for 5 s and primer annealing
and extension at 60°C for 20 s. Melting curves were generated for each ampliﬁed cDNA to check the speciﬁcity
of the reactions.
Flow cytometry analysis. Cells from tracheal aspirate samples were stained in PBS–2 mM EDTA–5% FBS
with a dead cell marker (Molecular Probes, Eugene, OR, USA) and anti-CD45-, anti-CD15-, anti-CD56-,
anti-CD16-, anti-CD14-, anti-CD11c-, anti-CD3-, and anti-CD19-conjugated antibodies (BD Biosciences, Le Pont
de Claix, France) for phenotyping. Analysis of intracellular antigens was performed on cells that were ﬁxed and
permeabilized by using the Cytoﬁx/Cytoperm kit from BD Biosciences (Le Pont de Claix, France) according to
the manufacturer’s recommendations. MDCK cells infected by inﬂuenza A viruses were stained with anti-
inﬂuenza A virus NP antibody conjugated with FITC (Abcam) or with the appropriate isotype control for 1 h
at 4°C in PBS with 2 mM EDTA and 5% FBS. KLK1 was detected in cells from tracheal aspirate samples by using
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FITC-conjugated anti-KLK1 (catalog number 1963R; Bioss, Woburn, MA, USA) incubated for 30 min at 4°C. For
KLK5 staining, the permeabilized cells were incubated with an anti-KLK5 antibody (catalog number 168340;
Abcam, Cambridge, UK) for 1 h at RT and then with a goat anti-rabbit IgG secondary antibody (Alexa Fluor
546 conjugate) for 30 min at 4°C. Appropriate isotype controls, NCI-H292 cells (deﬁcient in KLK1) and
unstimulated hBECs (deﬁcient in KLK5), were used to determine the speciﬁcity of the antibodies used. Flow
cytometric analyses were performed by using a MACS Quant analyzer (Miltenyi Biotec) and VenturiOne
software (AppliedCytometry).
Statistical analysis. Statistical analysis was performed by using GraphPad Prism (Prism 6 for Windows).
Statistical signiﬁcance between the different values was analyzed by a Mann-Whitney U test or one-way
analysis of variance (ANOVA) followed by Tukey’s multiple-comparison test according to the number of
parameters and groups being compared. A P value of 0.05 was considered signiﬁcant.
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